Strebel P M, Ion-Nedelcu N, Baughman A L, Sutter R W, Cochi S L
Epidemiology and Surveillance Division, Centers for Disease Control and Prevention, Atlanta, GA 30333.
N Engl J Med. 1995 Feb 23;332(8):500-6. doi: 10.1056/NEJM199502233320804.
In Romania the rate of vaccine-associated paralytic poliomyelitis is for unexplained reasons 5 to 17 times higher than in other countries. Long ago it was noted that intramuscular injections administered during the incubation period of wild-type poliovirus infection increased the risk of paralytic disease (a phenomenon known as "provocation" poliomyelitis). We conducted a case-control study to explore the association between intramuscular injections and vaccine-associated poliomyelitis in Romania.
The patients were 31 young children in whom vaccine-associated paralytic poliomyelitis developed from 1988 through 1992. Eighteen were vaccine recipients, and 13 had acquired the disease by contact with vaccine recipients. Each of these children was matched with up to five controls according to health center, age, and in the case of vaccine recipients, history of receipt of the live attenuated oral poliovirus vaccine. Data were abstracted from medical records that documented the injections administered in the 30 days before the onset of paralysis.
Of the 31 children with vaccine-associated disease, 27 (87 percent) had received one or more intramuscular injections within 30 days before the onset of paralysis, as compared with 77 of the 151 controls (51 percent) (matched odds ratio, 31.2; 95 percent confidence interval, 4.0 to 244.2). Nearly all the intramuscular injections were of antibiotics, and the association was strongest for the patients who received 10 or more injections (matched odds ratio for > or = 10 injections as compared with no injections, 182.1; 95 percent confidence interval, 15.2 to 2186.4). The risk of paralytic disease was strongly associated with injections given after the oral polio virus vaccine, but not with injections given before or at the same time as the vaccine (matched odds ratio, 56.7; 95 percent confidence interval, 8.9 to infinity). The attributable risk in the population for intramuscular injections given in the 30 days before the onset of paralysis was 86 percent (95 percent confidence interval, 66 to 95 percent); that is, we estimate that 86 percent of the cases of vaccine-associated paralytic poliomyelitis in this population might have been prevented by the elimination of intramuscular injections within 30 days after exposure to oral poliovirus vaccine.
Provocation paralysis, previously described only for wild-type poliovirus infection, may rarely occur in a child who receives multiple intramuscular injections shortly after exposure to oral poliovirus vaccine, either as a vaccine recipient or through contact with a recent recipient. This phenomenon may explain the high rate of vaccine-associated paralytic poliomyelitis in Romania, where the use of intramuscular injections of antibiotics in infants with febrile illness is common.
在罗马尼亚,疫苗相关麻痹型脊髓灰质炎的发病率出于不明原因比其他国家高5至17倍。很久以前就有人指出,在野生型脊髓灰质炎病毒感染的潜伏期进行肌肉注射会增加麻痹性疾病的风险(一种被称为“激发性”脊髓灰质炎的现象)。我们开展了一项病例对照研究,以探讨在罗马尼亚肌肉注射与疫苗相关脊髓灰质炎之间的关联。
患者为1988年至1992年期间发生疫苗相关麻痹型脊髓灰质炎的31名幼儿。18名是疫苗接种者,13名是通过与疫苗接种者接触而患病的。根据健康中心、年龄以及对于疫苗接种者而言的口服减毒活脊髓灰质炎病毒疫苗接种史,将这些儿童中的每一名与多达5名对照进行匹配。数据从记录了麻痹发作前30天内所进行注射的医疗记录中提取。
在31名患有疫苗相关疾病的儿童中,27名(87%)在麻痹发作前30天内接受了一次或多次肌肉注射,相比之下,151名对照中有77名(51%)(匹配比值比为31.2;95%置信区间为4.0至244.2)。几乎所有的肌肉注射都是抗生素注射,对于接受10次或更多次注射的患者,这种关联最为强烈(与未注射相比,注射≥10次的匹配比值比为182.1;95%置信区间为15.2至2186.4)。麻痹性疾病的风险与口服脊髓灰质炎病毒疫苗后进行的注射密切相关,但与在疫苗之前或同时进行的注射无关(匹配比值比为56.7;95%置信区间为8.9至无穷大)。在麻痹发作前30天内进行肌肉注射的人群归因风险为86%(95%置信区间为66%至95%);也就是说,我们估计通过在接触口服脊髓灰质炎病毒疫苗后30天内避免肌肉注射,该人群中86%的疫苗相关麻痹型脊髓灰质炎病例可能得以预防。
激发性麻痹此前仅在野生型脊髓灰质炎病毒感染中有所描述,在接触口服脊髓灰质炎病毒疫苗后不久接受多次肌肉注射的儿童中可能很少发生,这些儿童或是疫苗接种者,或是通过与近期接种者接触而感染。这一现象可能解释了罗马尼亚疫苗相关麻痹型脊髓灰质炎的高发病率,在罗马尼亚,对发热疾病患儿进行抗生素肌肉注射的情况很常见。